<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134198</url>
  </required_header>
  <id_info>
    <org_study_id>6013</org_study_id>
    <secondary_id>RU486 for Cocaine Dependence</secondary_id>
    <nct_id>NCT01134198</nct_id>
  </id_info>
  <brief_title>Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients</brief_title>
  <official_title>Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will evaluate the impact of blocking central and peripheral glucocorticoid
      receptors on stress sensitivity and the risk of relapse to cocaine use in treatment-seeking
      cocaine-dependent individuals. Mifepristone (RU-486) will be the glucocorticoid antagonist
      used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study attempts to reduce relapse risk by blocking glucocorticoid receptors, and thus
      allow some of the changes in the brain caused by cocaine to redress themselves
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 14, 2018</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Relapse by Days 10 and 28</measure>
    <time_frame>assessed during 8 weeks of trial, but reported for days 10 and 28 of trial</time_frame>
    <description>assessed percent of sample with documented cocaine use by days 10 and 28 based on self reported use and urine toxicology. Those with documented use were considered to have relapsed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mifepristone 600mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Mifepristone 600mg, 3x/wk for 4 weeks</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>RU486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 60.

          2. Male.

          3. Meets DSM?IV criteria for current cocaine dependence and is seeking treatment.

          4. Identifies life stress (work, interpersonal, financial, etc) as a trigger for cocaine
             use or reports uncontrollable craving to use of cocaine.

          5. Displays at least one cocaine-positive urine toxicology during screening.

          6. Uses cocaine at least 4/30 days in the past month, or reports episodic binges of large
             amounts of cocaine (at least $200) at least 2x/month.

          7. Able to give informed consent and comply with study procedures.

        Exclusion Criteria:

          1. Meets DSM-IV criteria for major depression, bipolar disorder, schizophrenia or any
             psychotic disorder other than transient psychosis due to drug abuse. Substance Induced
             Mood Disorder with Hamilton Depression Scale score ³13 will be excluded.

          2. History of seizures in the last 2 years, or history of seizures related to the
             substance (cocaine, alcohol, or benzodiazepine) that the patient continues to use.

          3. History of allergic, dermatological, or adverse event to mifepristone

          4. Chronic organic mental disorder, insufficient proficiency in English that would render
             an individual incapable of giving informed consent.

          5. Significant current suicidal risks, history of significant suicidal behavior or any
             suicide attempt within the past year.

          6. Unstable physical disorders, which might make participation hazardous such as
             hypertension (&gt;140/90), WBC &lt; 3.5, new diagnosis of hepatitis (patients with chronic
             mildly elevated transaminase levels (£2-3 X upper limit of normal will be considered
             acceptable if PT/PTT is normal), renal failure (creat &gt; 2; BUN &gt; 40), or diabetes
             (HbA1c &gt; 7%), and low Hb (&lt; 12g/dL) or low Hct (&lt;36%).

          7. Coronary vascular disease as indicated by history, or suspected by abnormal ECG or
             history of cardiac symptoms. Hx of cardiac symptoms (chest pain, chest pressure,
             shortness of breath, syncope) during cocaine use.

          8. Cardiac conduction system disease as indicated by QRS duration of ³ 0.11 msec.

          9. Currently meets DSM-IV criteria for another substance dependence or abuse disorder
             other than nicotine, alcohol, or cannabis. If alcohol dependent, must not be in need
             of detoxification. Heavy male drinkers (who consume greater than 5 standard alcoholic
             drink per day per NIAAA definition) will be excluded.

         10. Presents with metabolic indicators of hypoadrenalism such as low serum sodium (&lt;130
             mEq/L), high serum potassium (&gt;5.5 mEq/L), Na/K ratio &lt; 30:1, low fasting blood sugar
             (&lt;50 mg/dL), or high BUN (&gt;20 mg/dL), or a previous history of Addison's disease or
             adrenal insufficiency, or the presence of low K (&lt; 3.5 mEq/L). spot AM cortisol
             &lt;5ug/dL, PM cortisol &lt; 3 ug/dL

         11. Participants who cannot comply with study procedures during the initial
             hospitalization phase.

         12. Supplemental exclusion criteria for cold pressor test (CPT): history of frostbite,
             open cut or sore on foot to be immersed, history of Raynaud's phenomenon. During the
             testing, if sBP &gt; 190 or dBP &gt; 120, or HR &gt; 160, the test will be interrupted. A
             second occurrence of these values will stop all further CPT.

        13: Patients taking medications metabolized by cytochrome 3A4 (ex: erythromycin, protease
        inhibitors) or that inhibit this cytochrome; or consuming grapefruit juice.

        14: Patients with an underlying hemorrhagic disorder and those on anti-coagulants. INR &gt;
        1.1, PT &gt; 17 msecs, total plt &lt;100x109/L.

        15: Use of treatment agents that inhibit steroid biosynthesis by the adrenal cortex, such
        as metyrapone, ketoconazole, fluconazole, aminoglutethimide, or etomidate. Patients also
        requiring inhaled steroids.

        16. Female
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfid N Raby, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <results_first_submitted>June 1, 2018</results_first_submitted>
  <results_first_submitted_qc>August 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2018</results_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Wilfrid Raby</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cocaine Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data has been presented as an oral presentation at the annual meeting of the College on Drug Dependence in Palm Springs California on June 16th 2016. The data is presently being prepared for publication in a peer-reviewed publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>the data will be available by the end of 2018, and will be indefinitely</ipd_time_frame>
    <ipd_access_criteria>there will be no access criteria required</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>58 participants signed consent and were enrolled into the trial. Only 32 entered the randomized phase of the study with only 29 being assigned to one of the treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone</title>
          <description>Mifepristone 600mg
Mifepristone: Mifepristone 600mg, 3x/wk for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>demographics for 29 participants who were randomized and started Phase 1</population>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone</title>
          <description>demographics for 16 participants who were randomized and started Phase 1.
Mifepristone 600mg, 3x/wk for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>demographics for 13 participants who were randomized and started Phase 1.
Placebo 600mg, 3x/week for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="8.3"/>
                    <measurement group_id="B2" value="46" spread="8.3"/>
                    <measurement group_id="B3" value="46" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Relapse by Days 10 and 28</title>
        <description>assessed percent of sample with documented cocaine use by days 10 and 28 based on self reported use and urine toxicology. Those with documented use were considered to have relapsed.</description>
        <time_frame>assessed during 8 weeks of trial, but reported for days 10 and 28 of trial</time_frame>
        <population>participants entering phase 2 of trial</population>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone</title>
            <description>Mifepristone 600mg
Mifepristone: Mifepristone 600mg, 3x/wk for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapse by Days 10 and 28</title>
          <description>assessed percent of sample with documented cocaine use by days 10 and 28 based on self reported use and urine toxicology. Those with documented use were considered to have relapsed.</description>
          <population>participants entering phase 2 of trial</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <title>relapsed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>abstinent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <title>relapsed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>abstinent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 9 weeks (1 week of inpatient in phase 1 and 8 weeks in outpatient phase 2)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mifepristone</title>
          <description>Mifepristone 600mg
Mifepristone: Mifepristone 600mg, 3x/wk for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>elevated eosinophils</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>insomnia/hypersomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>wilfrid raby, md</name_or_title>
      <organization>new york state psychiatric institute</organization>
      <phone>212-923-3031</phone>
      <email>wilfrid.raby@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

